Research interests
We are concerned with the development of novel precision medicine approaches to treat cancer, and work to elucidate novel predictive biomarkers (genomic, transcriptomic, proteomic) and identify new therapeutic targets. To achieve our objectives, we especially employ highly disruptive multi-modality molecular imaging and Next Generation Sequencing (NGS) approaches. We have particular expertise implementing PDX and other clinically relevant disease models. The PCM group works primarily on colorectal and brain malignancies with an overall goal to improve patient outcomes.